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TeBACKGROUND Multiple randomized clinical trials comparing renal artery stent placement plus medical therapy
with medical therapy alone have not shown any beneﬁt of stent placement. However, debate continues whether
patients with extreme pressure gradients, stenosis severity, or baseline blood pressure beneﬁt from stent
revascularization.
OBJECTIVES The study sought to test the hypothesis that pressure gradients, stenosis severity, and/or baseline blood
pressure affects outcomes after renal artery stent placement.
METHODS Using data from 947 patients with a history of hypertension or chronic kidney disease from the largest
randomized trial of renal artery stent placement, the CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions)
study, we performed exploratory analyses to determine if subsets of patients experienced better outcomes after stent
placement than the overall cohort. We examined baseline stenosis severity, systolic blood pressure, and translesion
pressure gradient (peak systolic and mean) and performed interaction tests and Cox proportional hazards analyses for the
occurrence of the primary endpoint through all follow-up, to examine the effect of these variables on outcomes by
treatment group.
RESULTS There were no statistically signiﬁcant differences in outcomes based on the examined variables nor were there
any consistent nonsigniﬁcant trends.
CONCLUSIONS Based on data from the CORAL randomized trial, there is no evidence of a signiﬁcant treatment effect
of the renal artery stent procedure compared with medical therapy alone based on stenosis severity, level of systolic
blood pressure elevation, or according to the magnitude of the trans-stenotic pressure gradient. (Beneﬁts of Medical
Therapy Plus Stenting for Renal Atherosclerotic Lesions [CORAL]; NCT00081731) (J Am Coll Cardiol 2015;66:2487–94)
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2488M ultiple uncontrolled trials ofrenal artery angioplasty andstent placement report improved
patient outcomes (1–4). However, in the past
15 years there have been at least 5 random-
ized clinical trials investigating both surro-
gate endpoints and hard clinical endpoints
and none have shown any signiﬁcant beneﬁtof renal artery intervention plus medical management
compared with medical management alone (5–9).
Nonetheless, critics claim that the randomized clin-
ical trials are ﬂawed (10,11), and that with appropriate
patient selection renal artery intervention improves
patient outcomes. The most frequent criticisms
are that prior randomized trials enrolled subjects
with renal artery stenoses (RAS) that were not
hemodynamically or clinically signiﬁcant or excluded
patients with uncontrolled hypertension (12), or alter-
natively that patient selection should have been done
using translesional arterial pressure gradients (13).SEE PAGE 2495The CORAL (Cardiovascular Outcomes in Renal
Atherosclerotic Lesions) study was published in 2014
and included data from 947 patients with RAS who
were randomized to stent placement and medical
therapy or medical therapy alone (9). The CORAL
study showed no difference across a range of out-
comes by treatment group. We use data from the
CORAL study to examine the hypotheses that certain
patients with RAS in high-risk subgroups were more
likely to beneﬁt from stent placement.
METHODS
The CORAL study randomized 947 patients with either
refractory hypertension or chronic kidney disease to
optimal medical therapy versus optimal medical ther-
apy plus renal artery stent (9). The primary endpoint
was event free survival, with the “event” comprising a
composite endpoint of heart attack, stroke, hospitali-
zation for congestive heart failure, progressive renal
insufﬁciency or end-stage renal disease, and cardio-
vascular or renal-related death (9). A number of pre-
planned secondary analyses were also reported (9).
In the CORAL study, interaction tests were done
to assess whether the primary endpoint was affectedm Medtronic and Boston Scientiﬁc. Dr. Jamerson is a member of
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received June 22, 2015; revised manuscript received Septemberby selected physiologic variables in addition to
treatment group (9). Variables that were tested
included the presence or absence of bilateral RAS or
RAS with a single functioning kidney, baseline sys-
tolic blood pressure, and maximal renal artery
percent diameter stenosis (9). As an unplanned post-
hoc analysis, we examined these subgroups for
treatment group effect on clinical outcomes in more
detail by selecting speciﬁc thresholds to be examined.
Three hypotheses were tested: 1) patients with higher
percent stenosis at baseline would have better out-
comes after stent placement than with medical ther-
apy alone; 2) patients with higher intra-arterial
pressure gradients would have better outcomes after
stent placement compared with medical therapy
alone; and 3) patients with higher baseline blood
pressure would have better outcomes after stent
placement than with medical therapy alone. This was
an exploratory analysis done without adjustments for
multiple comparisons, an approach that entails a
relatively high risk of type I error. Furthermore, since
quartile subgroups are smaller populations than the
original sample statistical power for these analyses is
lower than for the study primary endpoint examined
in the original cohort.
For each of the variables examined (baseline per-
cent stenosis, baseline translesional pressure gra-
dient, and baseline systolic blood pressure), we
grouped participants according to historic thresholds
and also into quartiles as dictated by the data. For
baseline angiographic percent stenosis, we used both
the investigator-reported as well as the core lab
measured percent stenosis. For translesion pressure
gradients both peak mean and peak systolic pressure
gradients were examined. Cox proportional hazards
regression was applied to test treatment-by-subgroup
interaction for the composite primary endpoint.
Kaplan-Meier event-free survival rates between
treatment groups for all examined subgroups were
compared using log-rank tests.
RESULTS
The CORAL intention-to-treat population included
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TABLE 1 Number of Patients in Each Baseline Quartile Subgroup (by Treatment Group):
Randomized Patients
Subgroup
Stent
(n ¼ 459)
Medical Therapy
(n ¼ 472) Difference p Value
% Stenosis (core lab)
<60.22 23.1 (100/433) 27.3 (83/304) –4.2 [–10.6 to 2.2] 0.193
60.22 to <68.46 24.7 (107/433) 25.7 (78/304) –0.9 [–7.3 to 5.4] 0.770
68.46 to <77.05 27.3 (118/433) 22.0 (67/304) 5.2 [–1.1 to 11.5] 0.108
$77.05 24.9 (108/433) 25.0 (76/304) –0.1 [–6.4 to 6.3] 0.986
% Stenosis (investigator)
<69.7 24.9 (107/429) 25.7 (96/374) –0.7 [–6.8 to 5.3] 0.813
69.7 to <76 26.8 (115/429) 27.5 (103/374) –0.7 [–6.9 to 5.4] 0.816
76 to <85 19.8 (85/429) 25.9 (97/374) –6.1 [–11.9 to –0.3] 0.039
>85 28.4 (122/429) 20.9 (78/374) 7.6 [1.7 to 13.5] 0.013
Systolic blood pressure
<133.83 mm Hg 24.5 (112/457) 25.5 (119/467) –1.0 [–6.6 to 4.6] 0.732
133.83 to <149.34 mm Hg 25.6 (117/457) 24.8 (116/467) 0.8 [–4.8 to 6.4] 0.790
149.34 to <164.34 mm Hg 24.9 (114/457) 25.1 (117/467) –0.1 [–5.7 to 5.5] 0.970
$164.34 mm Hg 24.9 (114/457) 24.6 (115/467) 0.3 [–5.2 to 5.9] 0.910
Peak systolic pressure gradient
<26 mm Hg 21.5 (26/121) 30.8 (24/78) –9.3 [–21.9 to 3.3] 0.141
26 to <43 mm Hg 24.8 (30/121) 24.4 (19/78) 0.4 [–11.8 to 12.7] 0.945
43 to <65 mm Hg 28.1 (34/121) 19.2 (15/78) 8.9 [–3.0 to 20.7] 0.156
$65 mm Hg 25.6 (31/121) 25.6 (20/78) –0.0 [–12.4 to 12.4] 0.997
Mean systolic pressure gradient
<10 mm Hg 15.0 (17/113) 34.3 (24/70) –19.2 [–32.2 to –6.3] 0.002
10 to <19 mm Hg 30.1 (34/113) 21.4 (15/70) 8.7 [–4.1 to 21.5] 0.199
19 to <33 mm Hg 28.3 (32/113) 18.6 (13/70) 9.7 [–2.6 to 22.1] 0.137
$33 mm Hg 26.5 (30/113) 25.7 (18/70) 0.8 [–12.2 to 13.9] 0.901
Values are % (n/N) or % [95% conﬁdence interval].
TABLE 2 Number of Patients in Each Baseline Subgroup Categorized by Clinically
Signiﬁcant Thresholds (by Treatment Group): Randomized Patients
Subgroup
Stent
(n ¼ 459)
Medical Therapy
(n ¼ 472) Difference p Value
% Stenosis (core lab)
<60 23.1 (100/433) 26.3 (80/304) –3.2 [–9.6 to 3.1] 0.316
60 to <80 57.3 (248/433) 54.6 (166/304) 2.7 [–4.6 to 10.0] 0.472
$80 19.6 (85/433) 19.1 (58/304) 0.6 [–5.2 to 6.3] 0.852
% Stenosis (investigator)
<60 0.2 (1/429) 0.0 (0/374) 0.2 [–0.2 to 0.7] 0.350
60–<80 53.6 (230/429) 55.6 (208/374) –2.0 [–8.9 to 4.9] 0.570
$80 46.2 (198/429) 44.4 (166/374) 1.8 [–5.1 to 8.7] 0.615
Systolic blood pressure
<140 mm Hg 35.0 (160/457) 35.8 (167/467) –0.7 [–6.9 to 5.4] 0.812
140 to <160 mm Hg 31.9 (146/457) 33.8 (158/467) –1.9 [–7.9 to 4.2] 0.542
160 to <180 mm Hg 22.5 (103/457) 21.0 (98/467) 1.6 [–3.8 to 6.9] 0.567
$180 mm Hg 10.5 (48/457) 9.4 (44/467) 1.1 [–2.8 to 4.9] 0.583
Peak systolic pressure gradient
<20 mm Hg 9.1 (11/121) 7.7 (6/78) 1.4 [–6.4 to 9.2] 0.730
20 to <40 mm Hg 34.7 (42/121) 46.2 (36/78) –11.4 [–25.4 to 2.5] 0.106
$40 mm Hg 56.2 (68/121) 46.2 (36/78) 10.0 [–4.1 to 24.2] 0.166
Mean systolic pressure gradient
<10 mm Hg 15.0 (17/113) 34.3 (24/70) –19.2 [–32.2 to –6.3] 0.002
10 to <20 mm Hg 33.6 (38/113) 25.7 (18/70) 7.9 [–5.5 to 21.4] 0.259
$20 mm Hg 51.3 (58/113) 40.0 (28/70) 11.3 [–3.4 to 26.0] 0.136
Values are % (n/N) or % [95% conﬁdence interval].
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2489There were 4,375 potential participants screened
with a total of 4,672 exclusions. Most (54%) of the
reasons for nonenrollment were that participants
did not meet study eligibility criteria. Other reasons
included patient preference (17%), physician pref-
erence (4%), and other unspeciﬁed reasons (23%).
The baseline characteristics of this population have
been previously described (9). The distribution of
participants for each of the variables (baseline
percent stenosis, baseline systolic blood pressure,
baseline peak systolic pressure gradient, baseline
mean pressure gradient) by quartile is described in
Table 1, and the distribution using conventional
clinical thresholds of these variables is given in
Table 2. Tests of interaction for these variables did
not reveal any consistent treatment effect from
stent treatment group, using either quartiles or
clinically signiﬁcant thresholds for each of the var-
iables (Figures 1A and 1B, Central Illustration). Log-
rank tests used to compare Kaplan-Meier survival
free rates of the primary endpoint for both treat-
ment groups by stenosis category revealed no sta-
tistically signiﬁcant differences (Figures 2A to 2D).
Log-rank tests for differences in Kaplan-Meier
event-free survival rates for categories of baseline
systolic blood pressure, baseline peak systolic pres-
sure gradient, and baseline mean pressure gradient
were also not statistically signiﬁcant (not shown).
DISCUSSION
We performed an analysis of a prospective random-
ized clinical study designed to identify associations
or correlations that were not part of the original
pre-planned analysis. Such post-hoc analyses with
multiple comparisons pose a considerable risk of
type I error. Nevertheless, no signiﬁcant results were
observed that would suggest a beneﬁt for any of the
subgroups that have been regarded as important for
patient selection in the past (12,13). Each component
of the primary endpoint was also examined for re-
lationships with baseline blood pressure, stenosis
severity, and translesion pressure gradient, and all
were similarly negative (data not shown).
The CORAL study had a requirement for $60%
stenosis in a dominant renal artery for inclusion (14).
When the CORAL study was designed, it was felt that
this threshold was similar to those used clinically,
and therefore was essential for generalizability of
study results. Although a higher percent stenosis for
eligibility might have improved detection of a treat-
ment effect for stent placement, it would have been
applicable to a smaller subset than those treated in
clinical practice. These analyses demonstrate no
FIGURE 1 Freedom From the Primary Composite Endpoint Over Time in the CORAL Study Subgroups
Subgroup Stent Medical Therapy Hazard Ratio (95% CI) P–Value
Overall
Percent Stenosis [Core Lab]
     <60.22
     60.22–<68.46
     68.46–<77.05
     >=77.05
Percent Stenosis [Investigator]
     <69.7
     69.7–<76
     76–<85
     >=85
Baseline SBP
     <133.83
     133.83–<149.34
     149.34–<164.34
     >=164.34
Peak Systolic Pressure Gradient
     <26
     26–<43
     43–<65
     >=65
Mean Systolic Pressure Gradient
     <10
     10–<19
     19–<33
     >=33
35.1% (161/459)
40.0% (40/100)
38.3% (41/107)
27.1% (32/118)
39.8% (43/108)
35.5% (38/107)
29.6% (34/115)
40.0% (34/85)
39.3% (48/122)
26.8% (30/112)
37.6% (44/117)
26.3% (30/114)
50.0% (57/114)
30.8% (8/26)
33.3% (10/30)
38.2% (13/34)
45.2% (14/31)
35.3% (6/17)
32.4% (11/34)
46.9% (15/32)
43.3% (13/30)
35.8% (169/472)
33.7% (28/83)
42.3% (33/78)
32.8% (22/67)
50.0% (38/76)
33.3% (32/96)
39.8% (41/103)
40.2% (39/97)
39.7% (31/78)
32.8% (39/119)
31.9% (37/116)
35.9% (42/117)
41.7% (48/115)
41.7% (10/24)
47.4% (9/19)
46.7% (7/15)
35.0% (7/20)
33.3% (8/24)
60.0% (9/15)
38.5% (5/13)
27.8% (5/18)
0.94
1.19
0.85
0.75
0.72
1.07
0.66
0.88
0.94
0.74
1.28
0.64
1.21
0.51
0.69
0.60
1.31
0.99
0.42
1.29
1.53
(0.76,1.17)
(0.73,1.94)
(0.54,1.34)
(0.44,1.30)
(0.47,1.12)
(0.67,1.73)
(0.42,1.04)
(0.55,1.39)
(0.60,1.48)
(0.46,1.20)
(0.83,1.99)
(0.40,1.02)
(0.83,1.78)
(0.19,1.36)
(0.28,1.70)
(0.24,1.52)
(0.53,3.24)
(0.34,2.87)
(0.17,1.03)
(0.47,3.56)
(0.54,4.30)
0.58
0.42
0.49
0.48
0.31
0.15
0.53
0.77
0.07
0.57
0.80
0.05
0.22
0.27
0.06
0.32
0.55
0.18
0.42
0.28
0.56
0.23
0.99
0.06
0.62
0.42
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Subgroup Stent Medical Therapy Hazard Ratio (95% CI) P–Value
Overall
Percent Stenosis [Core Lab]
     <60
     60–<80
     >=80
Percent Stenosis [Investigator]
     <60
     60–<80
     >=80
Baseline SBP
     <140
     140–<160
     160–<180
     >=180
Peak Systolic Pressure Gradient
     <20
     20–<40
     >=40
Mean Systolic Pressure Gradient
     <10
     10–<20
     >=20
35.1% (161/459)
40.0% (40/100)
33.1% (82/248)
40.0% (34/85)
0% (0/1)
33.5% (77/230)
38.9% (77/198)
29.4% (47/160)
32.2% (47/146)
36.9% (38/103)
60.4% (29/48)
18.2% (2/11)
38.1% (16/42)
39.7% (27/68)
35.3% (6/17)
34.2% (13/38)
44.8% (26/58)
35.8% (169/472)
32.5% (26/80)
39.8% (66/166)
50.0% (29/58)
N/A
38.0% (79/208)
38.6% (64/166)
31.7% (53/167)
34.8% (55/158)
37.8% (37/98)
47.7% (21/44)
50.0% (3/6)
44.4% (16/36)
38.9% (14/36)
33.3% (8/24)
50.0% (9/18)
35.7% (10/28)
0.94
1.24
0.76
0.74
0.84
0.93
0.87
0.90
0.91
1.22
0.28
0.72
0.93
0.99
0.63
1.27
(0.76,1.17)
(0.75,2.04)
(0.55,1.06)
(0.45,1.23)
(0.61,1.15)
(0.67,1.30)
(0.58,1.29)
(0.61,1.34)
(0.58,1.43)
(0.69,2.17)
(0.05,1.69)
(0.36,1.46)
(0.49,1.78)
(0.34,2.87)
(0.27,1.47)
(0.61,2.63)
0.58
0.19
0.40
0.10
0.25
0.67
0.27
0.67
0.59
0.48
0.61
0.67
0.49
0.39
0.17
0.36
0.83
0.45
0.99
0.28
0.52
0 0.2 0.4 0.6 1 1.6 2.7
Hazard Ratio
Favor Stent Favor Medical Therapy
A
B
Forest plots displaying treatment effects within subgroups by quartiles (A) and by historic clinical thresholds (B): baseline percent stenosis (core lab),
baseline percent stenosis (investigator), baseline systolic blood pressure (SBP), baseline peak systolic pressure gradient, baseline mean systolic pressure
gradient (rates of primary endpoint composite through all available follow-up). The p values for rows labeled as percent stenosis, peak systolic pressure
gradient, mean systolic pressure gradient, and baseline SBP are treatment-by-subgroup interaction p values. The rest of the p values are for remaining
subgroups. CI ¼ conﬁdence interval; CORAL ¼ Cardiovascular Outcomes in Renal Atherosclerotic Lesions.
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CENTRAL ILLUSTRATION Renal Artery Stent Outcomes: Subgroups Analysis From the CORAL Study
>40
20-140
160-180
>180
>80
60-80
Percent Stenosis (Core Lab)
Baseline SBP
Peak Systolic Pressure Gradient
Hazard Ratio
Favor Stent/Favor Medical Therapy
Subgroup                                          Stent                 Medical Therapy                                                                                               P Value
0.58
0.19
0.40
0.10
0.25
0.59
0.48
0.61
0.67
0.49
0.17
0.39
0.83
0.36
Murphy, T.P. et al. J Am Coll Cardiol. 2015; 66(22):2487–94.
Forest plot displaying treatment effects within clinical-threshold subgroups: baseline percent stenosis (core lab), baseline systolic blood pressure
(SBP), and baseline peak systolic pressure gradient. The p values for rows labeled as percent stenosis, peak systolic pressure gradient, and
baseline SBP are treatment-by-subgroup interaction p values. The rest of the p values are for remaining subgroups. CORAL ¼ Cardiovascular
Outcomes in Renal Atherosclerotic Lesions.
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2491statistically signiﬁcant difference between stent
placement and medical therapy outcomes in CORAL
despite a number of thresholds for stenosis severity
examined, including for those with >80% stenosis
by core lab reading, where the hazard ratio for the
primary endpoint by treatment group falls almost
squarely on 1.0 (9).
One of the criticisms of the CORAL study and the
other clinical trials has been the inclusion of patients
with milder degrees of hypertension, for whom it
might be difﬁcult to see a beneﬁt of stenting (12).
However, the manuscript that was used to support
this contention was a meta-analysis of 5 clinical trials,
none of which had a medical control group (12). The
meta-analysis excluded almost one-half of the pa-
tients, and reported a mean reduction in systolic
blood pressure of 18 mm Hg at 9 months (12). How-
ever, it is known that physiologic variables that are
out of range often regress to the mean simply by
repeating the measure, as was observed in 1 clinical
trial of similar patients that had a run-in period
before interventional treatment was implemented
and found that systolic blood pressure was on average8 mm Hg lower after 4 weeks (5). In fact that reduc-
tion in systolic blood pressure reported by Weinberg
et al. (12) for renal artery stenting in those with
extreme blood pressure elevation is similar to that
observed in CORAL study in participants who were
treated in the medical therapy group (9). Blood
pressure improved in both the medical and stent
groups of CORAL, with the stent treated patients
having a greater reduction in blood pressure by
approximately 2.3 mm Hg (14). Finally, an interac-
tion test using a blood pressure threshold of
160 mm Hg systolic in the CORAL study (9) showed
no statistically signiﬁcant difference by treatment
groups in the primary endpoint. This post-hoc an-
alysis conﬁrms absence of statistically signiﬁcant
treatment effect of stenting in any of the categories
of baseline blood pressure examined. However, this
study is not deﬁnitive and lacks the power of the
original study due to parsing the population into
smaller subgroups.
It has also been postulated that a beneﬁt of stent
placement comparedwithmedical therapy alone could
have been shown for those patients with the most
FIGURE 2 Freedom From the Primary Endpoint by Subgroup in the CORAL Study
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(A) Event-free Kaplan-Meier curves for primary endpoint composite through 5 years of follow-up by treatment group for each baseline percent
stenosis as reported by the core lab quartile category (<60.22, 60.22 to <68.46, 68.46 to <77.05, $77.05 mm Hg). Log-rank test between
groups for ﬁrst quartile (<60.22) ¼ 0.4895. Log-rank test between groups for second quartile ¼ 0.4780. Log-rank test between groups for
third quartile ¼ 0.3065. Log-rank test between groups for fourth quartile ¼ 0.1487. The p value is for all available follow-up (not limited to
5 years). (B) Event-free Kaplan-Meier curves for primary endpoint composite through 5 years of follow-up by treatment group for each baseline
percent stenosis as determined by the core lab by clinically signiﬁcant category (<60, 60 to <80,$80 mm Hg). Log-rank test between groups
for ﬁrst category (<60) ¼ 0.3992. Log-rank test between groups for second category ¼ 0.1023. Log-rank test between groups for third
category ¼ 0.2487. The p value is for all available follow-up (not limited to 5 years). (C) Event-free Kaplan-Meier curves for primary endpoint
composite through 5 years of follow-up by treatment group for each baseline percent stenosis as reported by the investigator quartile category
(<69.7, 69.7 to <76, 76 to <85, $85 mm Hg). Log-rank test between groups for ﬁrst quartile (<69.7) ¼ 0.7703. Log-rank test between
groups for second quartile ¼ 0.0710. Log-rank test between groups for third quartile ¼ 0.5734. Log-rank test between groups for fourth
quartile ¼ 0.8009. The p value is for all available follow-up (not limited to 5 years). (D) Event-free Kaplan-Meier curves for primary endpoint
composite through 5 years of follow-up by treatment group for each baseline percent stenosis as reported by the investigator category
(60 to <80, $80 mm Hg). Log-rank test between groups for ﬁrst category (<60) ¼ N/A (there was no patient in Med Rx group, so the p value
is not available). Log-rank test between groups for second category ¼ 0.2736. Log-rank test between groups for third category ¼ 0.6663.
The p value is for all available follow-up (not limited to 5 years). CORAL ¼ Cardiovascular Outcomes in Renal Atherosclerotic Lesions.
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FIGURE 2 Continued
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2493severe translesional pressure gradients measured
intra-arterially (13). The CORAL study represents 1 of
the largest databases of patients with RAS and intra-
arterial translesion pressure gradients measured pro-
spectively, and the only study thatmeasured gradients
that had a group treated without revascularization.
Tests for interaction on various thresholds of intra-
arterial pressure gradients showed no difference in
outcomes for those with high versus lower transle-
sional pressure gradients by treatment group. Pressure
gradients, obtained mostly at operator discretion,
were measured in a small fraction of total participants
(n ¼ 199), but still represents the largest database
of renal artery pressure gradients in any clinical
trial. Another often-quoted manuscript that is thefoundation for many of the claims about the impor-
tance of renal artery pressure gradients was non-
randomized and included data from only 15 patients
(15). Furthermore, although the pressure gradient
cohort was a small fraction of the total, the centers of
the hazard ratios move toward medical therapy and
away from stenting as pressure gradients increase
(Figure 1). Tests for interaction on various thresholds of
intra-arterial pressure gradients showed no difference
in outcomes for those with high versus lower transle-
sional pressure gradients by treatment group.
STUDY LIMITATIONS. These detailed analyses were
not planned in the original study, and therefore in
addition to a risk of type I error, these analyses are
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Clinical outcomes in patients with RAS are not
improved by renal artery stenting regardless of
the severity of baseline hypertension or translesional
pressure gradient.
TRANSLATIONAL OUTLOOK: More research is
needed to determine whether speciﬁc patient features
such as impaired kidney function identify individuals
who might beneﬁt from renal revascularization.
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2494underpowered and entail a risk of type II error.
However, there were no trends, and as noted in the
discussion and seen in the Forest plot (Figure 1), for
some variables, like pressure gradients, hazard ratios
moved further to the medical therapy side as the
values moved to the higher values.
CONCLUSIONS
The CORAL study is the largest randomized clinical
trial comparing the effects of stenting and optimal
medical therapy alone in patients with RAS and hy-
pertension and/or chronic kidney disease, and suc-
cessfully recruited a broad range of patients reﬂective
of those often treated with renal artery stent place-
ment in clinical practice. A substantial proportion of
subjects in the CORAL study had high-grade stenoses,
severe systolic hypertension at entry, and signiﬁcant
translesional systolic pressure gradients. These vari-
ables have previously been felt to be important, but a
positive treatment effect of stenting in these sub-
groups was not observed. Speciﬁcally, the CORAL
study data does not support a beneﬁt of stenting
based on degree of stenosis, hemodynamic signiﬁ-
cance of the lesion, or higher pre-treatment blood
pressure.
Despite eligibility criteria that included high-risk
patients in CORAL, it is impossible to exclude selec-
tion bias among physicians referring patients for en-
try into an intervention trial. But because the CORALstudy’s population was similar in terms of risk to
those in uncontrolled studies that reported a beneﬁt
of stent placement (12,13), that potential criticism is
suspect. There were patients that were intentionally
excluded in CORAL, such as those with advanced
chronic kidney disease, a population that was
under represented in the CORAL study generally
and for whom inferences from these data are not
appropriate.
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